Gli individui a maggior rischio di complicanze sono adulti e bambini con patologie pregresse, i residenti in strutture socio-sanitarie e di lunga degenza, gli anziani oltre i 60 anni, le donne in gravidanza e alcune categorie professionali1.

Ai pazienti con patologie croniche, tra cui diabete, ipertensione, cardiopatie, asma o BPCO la vaccinazione antinfluenzale è infatti raccomandata e offerta gratuitamente1.

Di seguito alcune delle patologie maggiormente soggette a complicanze che l’influenza può portare con sé. Per ulteriori approfondimenti, e per un elenco completo delle condizioni cliniche in cui la vaccinazione è raccomandata, è possibile consultare le raccomandazioni del Ministero della Salute al seguente link.

    APPARATO RESPIRATORIO

    DIABETE MELLITO

    Sei un medico? Sono a disposizione ulteriori approfondimenti sulle complicanze nei pazienti diabetici al seguente link.

    APPARATO CARDIO-CIRCOLATORIO

    Sei un medico? Sono a disposizione ulteriori approfondimenti sulle complicanze nei pazienti affetti da patologie cardiovascolari al seguente link.

    TUMORI

    MALATTIE CORRELATE A IMMUNODEPRESSIONE

    INTERVENTI CHIRURGICI IMPORTANTI PROGRAMMATI

    MALATTIE INFIAMMATORIE CRONICHE (e malassorbimento intestinale)

    INSUFFICIENZA RENALE

    MALATTIE NEUROMUSCOLARI

    MALATTIE DEL SANGUE (e degli organi ematopoietici)

    EPATOPATIE CRONICHE

BIBLIOGRAFIA ESSENZIALE

1. Ministero della Salute, Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2023-2024 https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=93294&parte=1%20&serie=null;
2. Sandrock & Norris, Infection in Severe Asthma Exacerbations and Critical Asthma Syndrome, 2014;
3. Bekkat-Berkani et al., Seasonal influenza vaccination in patients with COPD: a systematic literature review, 2017;
4. Allard et al., Diabetes, and the severity of pandemic influenza A (H1N1) infection, 2010;
5. Diepersloot RJ, Bouter KP, Hoekstra JB. Diabetes Care. 1990 Aug;13(8):876-82;
6. Vamos EP, et al. Can Med Assoc J. 2016; 188: E342–51;
7. Modin et al. Diabetes Care. 2020 Sep;43(9):2226-2233;
8. Warren-Gash C, et al. Eur respir J. 2018;51(3):1701794;
9. Estabragh and Mamas, The cardiovascular manifestations of influenza: A systematic review, 2013;
10. Davidson JA, Banerjee A, Douglas I, et al. Primary prevention of acute cardiovascular events by influenza vaccination: an observational study. Eur Heart J. 2023;44(7):610-620. doi:10.1093/eurheartj/ehac737
11. CDC, Flu & Cancer https://www.cdc.gov/flu/highrisk/cancer.htm;
12. Li et al., Influenza in hospitalised patients with malignancy: a propensity score matching analysis, 2020;
13. https://www.aiom.it/influenza-vaccine-indication-during-therapy-with-immune-checkpoint-inhibitors-a-multicenter-prospective-observational-study-invidia-2/
14. Flu & People living with HIV https://www.cdc.gov/flu/highrisk/hiv-flu.htm;
15. Caldera et al., Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity, Vaccine 2021 Mar 15;39 Suppl 1:A15-A23;
16. Kunisaki & Janoff, Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses, Lancet Infect Dis 2009 Aug;9(8):493-504;
17. https://pubs.asahq.org/monitor/article/86/1/24/118112/Influenza-Persists;
18. Cheney et al., Adverse Respiratory Events Infrequently Leading to Malpractice Suits A Closed Claims Analysis, 1991;
19. Liu et al., Effect of Influenza Vaccination Against Postoperative Pneumonia and Mortality for Geriatric Patients Receiving Major Surgery: A Nationwide Matched Study, J Infect Dis 2018 Feb 14;217(5):816-826;
20. Barbalho et al., What Do Influenza and COVID-19 Represent for Patients With Inflammatory Bowel Disease?, Gastroenterology Res 2021 Feb;14(1):1-12;
21. Bower et al., Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?, Ann Rheum Dis, 2022 Mar;81(3):433-439;
22. The Lancet Reumatology Editorial, Fighting flu: the importance of vaccines in rheumatic disease https://doi.org/10.1016/S2665-9913(19)30161-4;
23. Kromer et al., Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso), Vaccines (Basel). 2021 Aug; 9(8): 843;
24. Flu & People with Chronic Kidney Disease https://www.cdc.gov/flu/highrisk/chronic-kidney-disease.htm;
25. Naqvi and Collins, Infectious Complications in Chronic Kidney Disease, 2006;
26. Wang IK, Lin CL, Lin PC, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One. 2013;8(3):e58317. doi:10.1371/journal.pone.0058317;
27. Raccomandazioni in tema di vaccinazioni in pazienti affetti da malattie neuromuscolari, a cura di M. Moggio et al., Associazione Italiana di Miologia (estratto da Vaccine, n. 32, pp. 5893–5900, 2014);
28. Crescimanno and Marrone, High frequency chest wall oscillation plus Mechanical In-Exsufflation in Duchenne muscular dystrophy with respiratory complications related to pandemic Influenza A/H1N1. Revista Portuguesa de Pneumologia, 2010, 16(6), 912–916;
29. Goldstein eta l., New CDC Recommendations: Annual Influenza Vaccination Recommended for Individuals With Spinal Cord Injuries, J Spinal Cord Med. 2005; 28(5): 383–384;
30. Atalla et al., Impact of Influenza Infection Among Adult and Pediatric Populations With Hematologic Malignancy and Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis, Clin Ther 2021 May;43(5):e66-e85;
31. Piñana JL, Pérez A, Montoro J, et al. Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. Clin Infect Dis. 2019;68(11):1894-1903. doi:10.1093/cid/ciy792;
32. Alukal et al., Vaccination in Chronic Liver Disease: An Update, 2022;
33. Härmälä S et al., Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ Open (2019) 9(9):e031070

Ultimo aggiornamento: 06/07/2023 | MAT-IT-2301542